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The activity of five (1-5) abietane phenol derivatives against Leishmania infantum and Leishmania braziliensis 
was studied using promastigotes and axenic and intracellular amastigotes. Infectivity and cytotoxicity tests were 
performed with J774.2 macrophage cells using Glucantime as a reference drug. The mechanisms of action were 
analysed by performing metabolite excretion and transmission electron microscopy ultrastructural studies. Com-
pounds 1-5 were more active and less toxic than Glucantime. The infection rates and mean number of parasites per 
cell observed in amastigote experiments showed that derivatives 2, 4 and 5 were the most effective against both L. 
infantum and L. braziliensis. The ultrastructural changes observed in the treated promastigote forms confirmed 
that the greatest cell damage was caused by the most active compound (4). Only compound 5 caused changes in the 
nature and amounts of catabolites excreted by the parasites, as measured by 1H nuclear magnetic resonance spec-
troscopy. All of the assayed compounds were active against the two Leishmania species in vitro and were less toxic 
in mammalian cells than the reference drug.
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Leishmaniasis, which is widely considered to be a 
“neglected disease”, is common in tropical and subtropi-
cal regions, including 22 countries in the New World 
and 66 in the Old World (who.int/leishmaniasis/). The 
etiological agents of this disease are different species of 
protozoa from the genus Leishmania, which are trans-
mitted by flies (Diptera) from the genus Phlebotomus 
in the Old World and from Lutzomyia in the New World. 
These species cause cosmopolitan or endemic diseases 
and present serious public health problems and leishma-
niasis is considered by the WHO to be one of the seven 
highest priority diseases that affect all continents.
Pentavalent antimonial compounds, such as sodium 
stibogluconate (Pentostam) and meglumine antimoni-
ate (Glucantime), have been recommended as first-line 
drugs for the treatment of leishmaniasis for 50 years. The 
most frequent side effects of these compounds, includ-
ing anorexia, vomiting, peripheral polyneuropathy and 
allergic dermopathy, are probably a result of oxidative 
or reductive damage to the host tissue. Thus, they are in-
extricably linked to the antiparasitic activity of the com-
pounds (Momeni et al. 2002, Natera et al. 2007, Palumbo 
2009). These effects make the development of new drugs 
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for the treatment of leishmaniasis a highly relevant and 
challenging research goal (Docampo & Moreno 1986, 
Cerecetto & Gonzalez 2002, Palumbo 2009).
One method of drug discovery involves the inves-
tigation of natural products obtained from medicinal 
plants (Braña et al. 2005). Indeed, folk medicines are 
often valid sources of bioactive substances that are po-
tentially useful in the treatment of many diseases, as 
demonstrated by the search for new medicinal agents 
for the treatment of trypanosomiasis, leishmaniasis and 
other diseases (Braña et al. 2005). In fact, a broad range 
of plant families and species contain active trypano-
cidal and leishmanicidal substances (Muhammad et al. 
2002, Cui et al. 2003, Takahashi et al. 2004, González 
et al. 2005, Tasdemir et al. 2006, Corrêa et al. 2011). For 
example, diterpene resin acids, which are found in co-
nifers, are known to be a potent defence against herbi-
vores and pathogens (Martin et al. 2002). Likewise, the 
reported biological activities of natural abietane acids 
include antimicrobial, antiulcer, cardiovascular, antial-
lergic, filmogenic, surfactant and anti-feedant properties 
(San Feliciano et al. 1993). The interest in this type of 
terpenoid has increased in recent years and has been en-
couraged by the isolation of several compounds, mainly 
phenols and related derivatives, with remarkable bio-
logical activities (Marrero et al. 2002, Tan et al. 2002). 
Other significant oxidised abietane diterpenes have been 
shown to strongly inhibit various human tumours and 
oncogene-transformed cells (Son et al. 2005). 
Our group has recently synthesised five novel abi-
etane phenols (Alvarez-Manzaneda et al. 2007a, b, c). To 
determine the benefits of these compounds, we studied 
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their in vitro antiproliferative activities against extra and 
intracellular forms of two species of Leishmania, Leish-
mania infantum and Leishmania braziliensis. The poten-
tial cytotoxicity of these compounds was also assessed 
using non-parasitised host cells to establish whether 
the in vitro activity of the metabolite is due to its gen-
eral cytotoxic activity or whether it is selectively active 
against Leishmania (Luque et al. 2000). Furthermore, 
we performed nuclear magnetic resonance spectroscopy 
(1H NMR) to determine the nature and percentages of 
the metabolites excreted by Leishmania and to clarify 
the potential of the compounds to inhibit the glycolyt-
ic pathway, which is the primary source of energy for 
the parasite. Finally, the effect of these compounds on 
the ultrastructure of Leishmania spp was monitored by 
transmission electron microscopy (TEM). 
MATERIALS AND METHODS
Chemical compounds - Compound 1, the methyl 
ester of 12-hydroxydehydroabietic acid, has recently 
been described as a new natural product (Kinouchi et 
al. 2000) and was synthesised from commercial abietic 
acid (Alvarez-Manzaneda et al. 2007b) (Fig. 1). Com-
pounds 2-4 were prepared from trans-communic acid 
(Alvarez-Manzaneda et al. 2007c), a labdane diterpene, 
that is very abundant in some species of Juniperus and 
Cupressus. Compound 3 is the methyl ester of lambertic 
acid, which was isolated from Podocarpus lambertius, 
and compound 4, 6,7-dehydroabieta-8,11,13-trien-12-
,19-diol, named sugikurojin A, is a new diterpene that 
was recently isolated from Cryptomeria japonica. Com-
pound 2, methyl-12,15-dihydroxyabieta-8,11,13-trien-
19-oate, has not yet been found in nature. Compound 
5, abieta-8,11,13-trien-14-ol, which was prepared from 
abietic acid (Alvarez-Manzaneda et al. 2007a), is an im-
mediate precursor in the synthesis of the antileishma-
nial agent 12-deoxyroyleanone.
Parasite strain culture - L. infantum (MCAN/
ES/2001/UCM-10) and L. braziliensis (MHOM/
BR/1975/M2904) were cultivated in vitro in medium 
trypanosomes liquid (MTL) containing 10% inactive 
foetal bovine serum (FBS) and were maintained in a 
standard air atmosphere at 28ºC in Roux flasks (Corn-
ing, USA) with a surface area of 75 cm2, as described by 
González et al. (2005). 
Cell culture and cytotoxicity tests - J774.2 mac-
rophages (ECACC 91051511) were originally obtained 
from a tumour in a female BALB/c mouse in 1968. The 
cytotoxicity test for macrophages was performed as de-
scribed by González et al. (2005). After 72 h of treatment, 
the cell viability was determined by flow cytometry. The 
cells were first incubated for 10 min with 100 µL/well of 
propidium iodide solution (100 mg/mL) at 28ºC in dark-
ness. Subsequently, 100 µL/well of fluorescein diacetate 
(100 ng/mL) was added and the cells were incubated un-
der the same conditions. Finally, the cells were recovered 
by centrifugation at 400 g for 10 min and the precipitate 
was washed with phosphate-buffered saline (PBS). Flow 
cytometric analysis was performed with a FACSVantage 
flow cytometer (Becton Dickinson, San Agustin de Gua-
dalix, Madrid, Spain). The percent viability was calcu-
lated in comparison to the control culture. The IC50 was 
calculated using linear regression analysis from the Kc 
values of the concentrations that were employed.
In vitro activity assay - Promastigote forms - The 
promastigote forms were collected in the exponential 
growth phase and distributed in culture trays (with 24 
wells) to a final concentration of 5 × 104 parasites/well. 
The compounds were dissolved in MTL and dimethyl 
sulphoxide (Panreac, Barcelona, Spain) at a concentra-
tion of 0.01%, after each compound was shown to be 
non-toxic and non-inhibitory of the growth of the para-
sites. The compounds were tested at final concentrations 
of 1-100 μM. The effects of each compound against the 
promastigote forms were tested at 72 h using a Neubauer 
haemocytometric chamber. The antileishmanial effects 
were expressed as IC50 values, i.e., the concentration 
required to produce 50% inhibition, which were calcu-
lated by linear regression analysis of the Kc values of the 
tested concentrations.
Amastigote assay - Cultures of J774.2 macrophages 
were grown in minimum essential medium with glu-
tamine (2 mM) supplemented with 20% inactive FBS 
and maintained in a humidified atmosphere containing 
95% air and 5% CO2 at 37ºC. The cells were seeded at 
a density of 1 × 104 cells/well in 24-well microplates Fig. 1: chemical structures of the terpenoid derivatives.
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(Nunc) with rounded coverslips on the bottom and cul-
tured for two days. Subsequently, the cells were infect-
ed with the promastigote forms of L. infantum and L. 
braziliensis in vitro at a ratio of 10:1 for 24 h. The non-
phagocytosed parasites were removed by washing and 
the macrophages were then incubated with the drugs (at 
1, 10, 25, 50 and 100 µM) for 72 h at 37ºC in 5% CO2. 
Drug activity was determined by the number of amas-
tigotes in treated and untreated cultures observed in meth-
anol-fixed, Giemsa-stained preparations. The number of 
amastigotes was determined by analysing 200 host cells 
distributed in randomly chosen microscopic fields. The 
antileishmanial effects were expressed as IC50 values.
Axenic amastigote assay - Axenic amastigote forms 
of L. braziliensis and L. infantum were cultured as de-
scribed by Moreno et al. (2011). The promastigotes were 
transformed into amastigotes by culturing for three days 
in M199 medium (Invitrogen, Leiden, The Netherlands) 
supplemented with 10% heat-inactivated foetal calf se-
rum, 1 g/L β-alanine, 100 mg/L L-asparagine, 200 mg/L 
sucrose, 50 mg/L sodium pyruvate, 320 mg/L malic acid, 
40 mg/L fumaric acid, 70 mg/L succinic acid, 200 mg/L 
α-ketoglutaric acid, 300 mg/L citric acid, 1.1 g/L sodium 
bicarbonate, 5 g/L 2-[morpholino]ethanesulfonic acid, 
0.4 mg/L hemin and 10 mg/L gentamicin at a pH of 5.4 
at 37ºC. The effect of each compound against the axenic 
amastigote forms was tested for 48 h using a Neubauer 
haemocytometric chamber. The antileishmanial effects 
were expressed as IC50 values.
Infection assay - The J774.2 macrophage cells were 
grown for two days under the same conditions used in 
the amastigote assay and subsequently infected in vitro 
with the promastigote forms of L. infantum and L. bra-
ziliensis at a ratio of 10:1. The drugs (IC25 concentra-
tions) were added at the same time and the cells were 
incubated for 12 h at 37ºC in an atmosphere containing 
5% CO2. The non-phagocytosed parasites and the drugs 
were removed by washing and the infected cultures were 
subsequently grown for 10 days in fresh medium. Fresh 
culture medium was added every 48 h. The drug activ-
ity was determined based on the percentage of infected 
cells and the number of amastigotes per infected cell (in 
treated and untreated cultures) in methanol-fixed, Giem-
sa-stained preparations. The percentage of infected cells 
and the mean number of amastigotes per infected cell 
were determined by analysing 200 host cells distributed 
in randomly chosen microscopic fields.
Metabolite excretion - Cultures of L. infantum and L. 
braziliensis promastigotes (initial concentration 5 × 105 
cells/mL) received IC25 concentrations of the compounds 
(except for the control cultures). After incubation for 96 h 
at 28ºC, the cells were centrifuged at 400 g for 10 min. 
The supernatants were collected and the excreted me-
tabolites were evaluated with 1H NMR; the chemical 
displacements were expressed in parts per million us-
ing sodium 2,2-dimethyl-2-silapentane-5-sulphonate as 
the reference signal. The chemical displacements used to 
identify the respective metabolites were consistent with 
those described by Fernández-Becerra et al. (1997). 
Ultrastructural changes - The parasites were cul-
tured at a density of 5 × 105 cells/mL in MTL medium 
containing drugs at the IC25 concentration. After 96 h, 
those cultures were centrifuged at 400 g for 10 min. The 
resulting cell pellets were washed in PBS, mixed with 
2% (v/v) p-formaldehyde-glutaraldehyde in 0.05 M ca-
codylate buffer (pH 7.4) for 4 h at 4ºC and prepared for 
TEM as described by González et al. (2005).
RESULTS
In vitro antileishmanial activity - The IC50 values 
that were registered 72 h after the exposure of the pro-
mastigote forms, axenic amastigote forms and intracel-
lular amastigote forms of L. infantum and L. braziliensis 
to compounds 1-5 were determined and are shown in 
Table. The values for the reference drug Glucantime are 
also included for comparison. 
The results displayed in Table show that the leish-
manicidal activities of compounds 1-5 are similar to 
and, in most cases, higher than that found for Glucantime 
for both the extra and intracellular forms of L. infantum. 
The toxicity data are more revealing; all five compounds 
that were tested proved to be far less toxic to macrophag-
es than the reference drug. Compounds 5 and 4 were 31 
and 25-fold less toxic than Glucantime, respectively, and 
even the most toxic of the derivatives (compound 1) is 
12-fold less toxic than Glucantime. The highest selectiv-
ity index (SI) values were found for compounds 5, 4 and 
3; these values exceeded those of the reference drugs by 
36, 36, and 36-fold in the case of 5, 34, 40 and 34-fold 
for 4, and 21, 28 and 26-fold for 3 for the promastigote, 
axenic amastigote and intracellular amastigote forms of 
L. infantum, respectively. 
Very similar conclusions can be drawn from the re-
sults for L. braziliensis, which are shown in Table. Com-
pounds 5 and 4 again gave the best SI values in the three 
assays that were performed, with values exceeding those 
of the reference drugs by 37, 52 and 37-fold in the case 
of 5 and by 32, 24 and 22-fold for 4. Compound 2 also 
showed very good SI values, which were slightly higher 
than those for compound 4.
Different authors have claimed that a compound 
should have an SI value 20-fold higher than that of the 
reference to be considered to possess leishmanicidal 
properties (Nwaka & Hudson 2006). This requirement is 
satisfied by compounds 2-5 against both L. infantum and 
L. braziliensis. Compound 1 was not included in further 
studies due to its low SI values.
The effect of compounds 2-5 on the intracellular rep-
lication of the amastigote forms was determined. The 
macrophages were grown and infected with promasti- 
gotes in the stationary phase. The parasites invaded the 
cells and were converted to amastigotes within one day 
after infection and the rate of host-cell infection reached 
its maximum on day 10 (control experiment). The IC25 of 
each product was used as the test dosage in these assays 
and Glucantime was the reference drug. As shown in 
Fig. 2A, the addition of compounds 2-5 to macrophage 
cells infected with L. infantum promastigotes caused a 
significant decrease in the infection rate with respect to 
the control and all of the compounds tested proved to be 
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more effective than Glucantime. Compounds 5 and 2 (in-
fectivity reduction of 93% and 85%, respectively) were 
the most effective. Calculations of the average number 
of amastigotes per infected macrophage cell (Fig. 2C) 
supported these conclusions; all four compounds proved 
to be much more effective than Glucantime, which had 
only a 59% decrease in the number of amastigotes per 
infected macrophage. 
The same experiment was performed with L. bra-
ziliensis and resulting infection rates and numbers of 
amastigotes per cell are presented in Fig. 2B, D, respec-
tively. In both cases, all four compounds (2-5) were more 
effective than Glucantime and compounds 5 and 2 again 
proved to be the most active. 
Studies on the mechanism of action - We performed 
several experiments to elucidate a possible mechanism 
of action for the abietane phenols 2-5 on the parasite.
Metabolite excretion effect - Leishmania species 
have a high rate of glucose consumption, which results 
in the acidification of the culture medium due to the in-
complete oxidation of glucose. 1H NMR spectroscopy 
enables the identification of the fermented metabolites 
excreted by the parasites during in vitro culture. Fig. 3A 
shows the spectrum produced by cell-free medium four 
days after inoculation with L. infantum. The peaks that 
correspond to the major metabolites produced and ex-
creted during growth were apparent when this spectrum 
was compared with that of the fresh medium (spectra not 
shown). L. infantum excretes succinate and acetate as its 
major metabolites. The 1H NMR spectra of the medium 
from drug-treated cells showed that only compound 5 
significantly altered the metabolites excreted by L. in-
fantum. When the promastigote forms of L. infantum 
were treated with compound 5 at IC25 doses, the excre-
tion of the catabolites succinate and acetate was clearly 
altered (Fig. 2B) and a new peak, which was subsequent-
ly identified as pyruvate, appeared in the spectrum. 
All compounds exhibited similar behaviour towards L. 
braziliensis and compound 5 again appeared to have the 
largest inhibitory effect (spectra not shown). 
Ultrastructural changes - TEM revealed substantial 
morphological alterations in Leishmania spp promastig-
otes after treatment with the newly synthesised abietane 
phenols 2-5 compared with the control sample (Fig. 4). 
All of the tested compounds induced alterations in L. 
infantum promastigotes, but only compounds 4 and 5 
proved to affect L. braziliensis. The ultrastructural al-
terations induced by these compounds in the two Leish-
mania species can be seen in Fig. 4.
The derivative that was most effective against L. in-
fantum was compound 4 (Fig. 4C), which induced the 
marked formation of vacuoles, some of which were com-
pletely empty, while others contained cellular debris. In 
some cases, these vacuoles occupied the entire cytoplasm 
and the parasites appeared swollen and deformed with 
swollen kinetoplasts and mitochondria. Some parasites 
TABLE
In vitro activity, toxicity and selectivity index found for the reference drugs and the terpenoides derivatives  
on promastigote, axenic amastigote and amastigote forms of Leishmania spp 
Leishmania infantum
Compounds
(IC50 µM)
Toxicity (IC50 µM) 
on J774.2 фa
Selectivity indexb
Promatigote
Axenic 
amastigote
Intracells 
amastigote Promatigote
Axenic 
amastigote
Intracells 
amastigote
Glucatime® 18.0 ± 1.1 30.0 ± 3.4 31.1 ± 5.7 15.2 ± 1.0 0.8 0.5 0.5
1 17.8 ± 3.3 27.5 ± 3.1 26.3 ± 3.9 189.6 ± 10.8 11 (14) 7 (14) 7 (14)
2 18.5 ± 2.1 18.9 ± 2.1 25.6 ± 3.0 257.6 ± 16.1 14 (17) 13 (26) 10 (20)
3 17,7 ± 0.4 20.9 ± 0.8 22.3 ± 2.6 300.0 ± 15.3 17 (21) 14 (28) 13 (26)
4 14.0 ± 1.5 19.2 ± 1.3 22.3 ± 1.8 379.0 ± 9.9 27 (34) 20 (40) 17 (34)
5 16.1 ± 2.4 26.3 ± 2.7 26.6 ± 6.3 467.4 ± 22.2 29 (36) 18 (36) 18 (36)
Leishmania braziliensis
Glucatime® 25.6 ± 1.6 29.6 ± 2.5 28.3 ± 4.3 15.2 ± 1.0 0.6 0.5 0.6
1 24.9 ± 5.7 40.1 ± 2.7 35.0 ± 5.5 189.6 ± 10.8 8 (13) 5 (10) 5 (8)
2 13.0 ± 1.5 15.7 ± 1.4 18.0 ± 2.8 257.6 ± 16.1 20 (33) 16 (32) 14 (23)
3 19.5 ± 0.5 30.9 ± 2.8 26.5 ± 2.9 300.0 ± 15.3 15 (25) 10 (20) 11 (19)
4 19.6 ± 1.1 31.6 ± 1.7 29.0 ± 4.0 379.0 ± 9.9 19 (32) 12 (24) 13 (22)
5 20.7 ± 5.2 18.0 ± 0.8 21.2 ± 2.2 467.4 ± 22.2 22 (37) 26 (52) 22 (37)
a: on J774.2 macrophages cells after 72 h of culture. IC50 = the concentration required to give 50% inhibition calculated by linear 
regression analysis from the Kc values at concentrations employed (1, 10, 25, 50 and 100 µM); b: selectivity index (SI) = IC50 vero 
cells/IC50 promastigote, axenic amastigote, intracells amastigote forms. In brackets: number of times that compound SI exceeds 
the reference drug SI. Average of three separate determinations.
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were filled with lipid vacuoles. In addition, circular struc-
tures that were similar to glycosomes, but were strongly 
electrodense and may have contained metabolic products 
of the parasites, were observed; these structures were not 
observed in the untreated parasites. Likewise, numerous 
promastigotes were found to be strongly electrodense and 
the cytoplasmic organelles could not be distinguished. 
Although the remaining compounds were less effective 
against L. infantum, they all induced the formation of large 
numbers of empty vacuoles or cellular debris that resulted 
from the destruction of the parasites (data not shown).
Compound 4 was also the most effective against L. 
braziliensis, as shown in panel 4 of Fig. 4. In this case, 
a high percentage of the parasites appeared to be de-
formed and to contain vacuoles, which were either emp-
ty or filled with membranous structures and occupied 
almost the entire cytoplasm. Many of the parasites were 
strongly electrodense and appeared to be dead.
DISCUSSION
Natural products from plants are frequently studied 
by researchers in attempts to identify bioactive substanc-
es that could be useful against various diseases (Braña 
et al. 2005). The isolation and structural elucidation of 
sulphated glucoside and seco-A-ring oleanane-type 
triterpenoids has recently been described and the anti-
leishmanial activity of these compounds has been exam-
ined. The results showed that the acylated seco-A ring 
oleanane derivatives are active, while the tricarboxylic 
acids are inactive (Macahig et al. 2011).
PX-6518 (1,10 13,28-epoxy-oleanane triterpene sa-
ponin) possesses potent in vivo activity against cutane-
ous (Inocêncio da Luz et al. 2011) and visceral (Maes et 
al. 2004) Leishmania species. 
A previous study indicated that the newly synthesised 
abietane phenols 1-5 are prospective chemotherapeutic 
drugs for the treatment of diseases caused by Trypano-
soma cruzi (unpublished observations). Most studies 
on the in vitro biological activity of new compounds 
against Leishmania spp are performed on the promasti- 
gote forms because they are much easier to work with in 
vitro. However, because extracellular forms are not the 
developed forms of the parasite in vertebrate hosts, stud-
ies using the extracellular forms are merely indicative of 
the potential leishmanicidal activity of the tested com-
pounds. Consequently, a preliminary test using extracel-
lular promastigote forms should always be complement-
ed by a subsequent evaluation using intracellular forms 
(amastigotes in vertebrate host cells) to better evaluate 
the true leishmanicidal activity of the tested compounds 
Fig. 2: effect of terpenoid derivatives on J774.2 macrophages infected with Leishmania infantum (A, C) and Leishmania braziliensis (B, D). 
Each value is the mean of three separate experiments. ▲: control; : Glucantime; ●: compound 2; +: compound 3; ♦: compound 4; □: compound 
5 (at IC25 concentration). 
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(González et al. 2005). Therefore, we chose to study the 
activity on both intra and extracellular forms.
The inhibitory effect of abietane compounds on pro-
mastigote forms has been studied previously. Totarol, 
ferruginol and 7β-hydroxyabieta-8,13-diene-11,12-dione 
have shown potent antileishmanial activity (IC50 values 
of 3.5–4.6 µg/mL vs. 1.3 µg/mL for pentamidine) against 
Leishmania donovani promastigotes (Samoylenko et al. 
2008). Abietane derivatives have also shown appreciable 
in vitro antileishmanial activity against the intracellular 
Fig. 3: 1H nuclear magnetic resonance spectroscopy spectra of promas-
tigote forms of Leishmania infantum. Control (A) and treated (B) with 
compound 5 at the concentration of IC25 (8 µM). ac: acetate [singlet, 
1.94 parts per million (ppm)]; ala: L-alanine (doublet, 1.5 ppm, 7.25 Hz); 
DMSO: dimethyl sulfoxide; lac: lactate (doublet, 1.35 ppm, 6.84 Hz); 
pyr: pyruvate (singlet, 2.26 ppm); suc: succinate: (singlet, 2.43 ppm). 
Fig. 4: transmission electron microscopy images of the ultrastructural alterations induced in Leishmania infantum and Leishmania braziliensis 
upon treatment with terpenoid derivatives. A: control parasite of L. infantum showing organelles with their characteristic aspect (Bar = 7.000); 
B: control parasite of L. braziliensis (Bar = 4.400): C: L. infantum treated with compound 4 showing intense vacuolisation and abundant electro-
dense structures (arrow) (Bar = 7.000); D: L. braziliensis treated with compound 4. Some parasites are more electrodense (arrow), deformed and 
with intense vacuolisation (Bar = 4.400); F: flagellum; G: glycosomes; K: kinetoplast; LV: lipid vacuoles; M: mitochondrion; N: nucleus.
amastigote forms of L. donovani and Leishmania major 
in other studies (Tan et al. 2002).
Our results indicate that the leishmanicidal activity of 
these compounds against both the extra and intracellular 
forms of L. infantum and L. braziliensis is similar to that 
of the reference drug Glucantime, but they are less toxic 
to host cells. Furthermore, the infection rate decreased 
significantly upon treatment with these drugs. To the best 
of our knowledge, none of the previously studied try-
panosomatids is capable of completely degrading glucose 
to CO2 under aerobic conditions, which means that they 
excrete a large proportion of their carbon skeleton into the 
medium as fermented metabolites, the profile of which 
differs according to the species (Bringaud et al. 2006).
Similar to T. cruzi (Ginger 2005), Leishmania spp 
excretes succinate as one of its major metabolites. The 
primary role of this metabolite is likely to maintain the 
glycosomal redox balance by providing two glycosomal 
oxidoreductase enzymes. These enzymes allow the reox-
idation of NADH, which is produced by glyceraldehyde-
3-phosphate dehydrogenase in the glycolytic pathway. 
Succinic fermentation offers one significant advantage 
in that it requires only half of the phosphoenolpyruvate 
(PEP) produced to maintain the NAD+/NADH balance. 
The remaining PEP may be converted into acetate, de-
pending on the species.
The metabolite profile observed when the parasites 
were cultured in the absence of compounds 2-5 was 
consistent with the findings of other authors (Ginger 
2005). The new peak that appeared when the promastig-
ote forms were treated with compound 5 at IC25 doses, 
which was subsequently identified as pyruvate, showed 
that compound 5 inhibits the glycosomal enzymes and 
causes pyruvate to be excreted as a final metabolite. 
The sesquiterpene polygodial, which was isolated 
from stem barks of Drimys brasiliensis, affected the 
Leishmania mitochondria (Corrêa et al. 2011).
The ultrastructural alterations induced by the terpe-
noid-based products studied here, especially compound 
4, on extracellular forms of L. infantum and L. brazi- 
liensis can explain the changes observed in the meta-
bolic studies, primarily their effect on the cytoplasm, 
kinetoplasts and mitochondria. 
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Thus, these in vitro results show that terpenoid com-
pounds are potentially promising agents for the treat-
ment of Leishmania infection. Further in vivo studies 
are warranted to further evaluate this potential.
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